Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
HRTX
#3019
Heron Therapeutics, Inc.
1.1
9
-0.83%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-0.83%
Aylık değişim
-14.39%
6 aylık değişim
-11.85%
Yıllık değişim
-39.90%
Önceki kapanış
1.2
0
Open
1.1
9
Bid
Ask
Low
1.1
9
High
1.1
9
Hacim
58
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
HRTX
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
91.4 M
102.14 M
119.26 M
150.33 M
152.33 M
188.54 M
—
Valuation ratios
Enterprise value
1.83 B
842 M
274.44 M
255.44 M
207.26 M
217.5 M
1.03 B
Price to earnings ratio
—
—
-1.46
-2.36
-17
-10.83
-165
Price to sales ratio
—
—
2.46
2.05
1.62
—
—
Price to cash flow ratio
—
—
1.8
4.44
10.35
7.85
43.64
Price to book ratio
—
—
19.49
7.68
6.93
16.32
23.56
Enterprise value to EBITDA ratio
279.79
239.48
15.14
16.78
3.78
—
—
Profitability ratios
Return on assets %
0.64
0.72
0.73
0.5
0.06
0.08
0.08
Return on equity %
0.96
2.84
13.41
3.25
0.4
1.41
1.21
Return on invested capital %
1 091.33
872.93
674.56
465.61
48.29
8.33
—
Gross margin %
59.15
46.7
49.04
48.75
73.21
73.31
293.19
Operating margin %
257.52
252.27
162.21
87.07
7.99
1.64
7.58
EBITDA margin %
7.38
4.07
16.83
11.98
37.96
46.87
148.46
Net margin %
256.52
255.58
169.03
87.02
9.41
13.04
52.44
Liquidity ratios
Quick ratio
2.66
2.9
1.83
1.84
1.7
1.51
5.58
Current ratio
3.07
3.58
2.49
2.37
2.29
2.48
8.25
Inventory turnover
1.08
1.02
1.07
1.35
0.81
0.57
0.61
Asset turnover
0.2
0.26
0.39
0.54
0.63
0.63
0.64
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
0.49
0.59
0.67
0.64
0.13
1.54
Long term debt to total equity ratio
—
1.92
11
4.4
4.45
2.28
15.2
Per share metrics
Operating cash flow per share
—
—
1.35
0.43
0.15
0.17
0.16
EBIT per share
—
—
0.14
0.09
0.34
0.42
0.31
EBITDA per share
—
—
0.17
0.11
0.36
0.44
0.33
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
0.78
0.58
0.39
0.28
1.13
Net current asset value per share
—
—
1.89
1.37
1.37
1.43
5.23
Tangible book value per share
—
—
0.12
0.25
0.22
0.08
0.44
Working capital per share
—
—
1.13
0.79
0.77
0.85
1.99
Book value per share
—
—
0.12
0.25
0.22
0.08
0.44
Haberler
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeuti kazancı beklentilere göre daha kötü, kâr ise beklentilere göre yüksek
Heron Therapeuti earnings missed, revenue topped estimates
Heron’un 4Ç 2025 sunumu: akut bakım atılımı ZYNRELEF’te %48 büyüme sağladı
Heron Q4 2025 slides: acute care surge drives 48% ZYNRELEF growth
Heron Therapeutics hisseleri güçlü 4. çeyrek gelir büyümesiyle yükseldi
Heron Therapeutics stock soars after strong Q4 revenue growth
Heron’s APONVIE featured in new postoperative nausea guidelines
Jefferies, Heron Therapeutics’in onkoloji franchise’ının düşüşü nedeniyle hedef fiyatını düşürdü
Jefferies lowers Heron Therapeutics stock price target on oncology franchise decline
Heron Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:HRTX) 2025-11-04
Heron Therapeutics 2025 3. Çeyrek: Kazanç Beklentilerini Karşılayamasa da Güçlü Ürün Büyümesi